Wellington Management Co. LLP recently announced the acquisition of new stake in Immatics N.V. (NASDAQ:IMTX). This fresh investment now brings its stake to 2.48% valued currently at $16.36 million. In addition, Rock Springs Capital Management L raised its holdings by 0.55 million to 1.68 million shares. And Sphera Funds Management Ltd. has lifted its position by 8.85% or 64694.0 shares – to 0.8 million shares.
With over 0.23 million Immatics N.V. (IMTX) shares trading Friday and a closing price of $8.80 on the day, the dollar volume was approximately $2.06 million. The shares have shown a positive half year performance of 2.09% and its price on 01/13/23 gained nearly 3.53%. Currently, there are 65.63M common shares owned by the public and among those 64.22M shares have been available to trade.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Immatics N.V. are Federated Hermes Kaufmann Small C, Hartford Small Company Fund, and JPMorgan Funds – Thematics – Gene. Federated Hermes Kaufmann Small C owns 1.41 million shares of the company’s stock, all valued at over $12.25 million. JPMorgan Funds – Thematics – Gene bought 0.15 million shares to bring its total holdings to over 0.18 million shares at a value of $1.57 million. JPMorgan Funds – Thematics – Gene now owns shares totaling to 0.24% of the shares outstanding.
However, the script later moved the day high at 8.90, up 3.53%. The company’s stock has a 5-day price change of -6.78% and -22.05% over the past three months. IMTX shares are trading 1.03% year to date (YTD), with the 12-month market performance down to -26.54% lower. It has a 12-month low price of $5.75 and touched a high of $13.60 over the same period. IMTX has an average intraday trading volume of 144.59K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.05%, -10.75%, and -8.67% respectively.
Institutional ownership of Immatics N.V. (NASDAQ: IMTX) shares accounts for 29.20% of the company’s 65.63M shares outstanding. Mutual fund holders own 25.13%, while other institutional holders and individual stakeholders account for 3.38% and — respectively.
It has a market capitalization of $653.40M and a beta (3y monthly) value of 0.55. The stock’s trailing 12-month PE ratio is 14.74, while the earnings-per-share (ttm) stands at $0.60. The company has a PEG of 1.21 and a Quick Ratio of 2.60 with the debt-to-equity ratio at 0.14. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.90% over the week and 6.16% over the month.
Analysts forecast that Immatics N.V. (IMTX) will achieve an EPS of -$0.44 for the current quarter, -$0.36 for the next quarter and -$1.55 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.68 while analysts give the company a high EPS estimate of -$0.22. Comparatively, EPS for the current quarter was -$0.49 a year ago. Earnings per share for the fiscal year are expected to increase by 66.30%, and -362.70% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Immatics N.V. (IMTX) as a “Strong Buy” at a consensus score of 1.30. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the IMTX, a number of firms have released research notes about the stock. BofA Securities stated their Buy rating for the stock in a research note on November 20, 2020, with the firm’s price target at $13. Goldman coverage for the Immatics N.V. (IMTX) stock in a research note released on September 22, 2020 offered a Buy rating with a price target of $17.
